Skip to main content
. 2019 Aug 23;20:58. doi: 10.1186/s12910-019-0395-5

Fig. 2.

Fig. 2

The schema of NCI-MATCH study design. The biopsy material derived from registered patients is characterized for specific pre-defined mutations via genetic sequencing. If an actionable mutation is detected, patients are assigned to 1 of 30 treatment sub-protocols. Those experiencing disease progression or serious adverse events undergo review of their previous biopsy results or undergo another biopsy to search for alternative treatment [10]